Access
To read this article in full you may need to log in, make a payment or gain access through a site license (see right).
News
Nature Biotechnology 26, 11–12 (1 January 2008) | doi:10.1038/nbt0108-11
News in brief
Abstract
India's biotech budget, Astellas' antibody splurge, Celgene swallows Pharmion, New Jersey stem cell plan thrown out, Selected research collaborations, AAV gene therapy restart, IP and iPS cells, Pfizer acquires Coley, New product approval
To read this article in full you may need to log in, make a payment or gain access through a site license (see right).
